Short interest for Yield10 Bioscience gives investors a sense of the degree to which investors are betting on the decline of Yield10 Bioscience's stock. Short interest data is updated every two weeks.

Yield10 Bioscience Stock (NASDAQ:YTEN), Short Interest Report

Yield10 Bioscience

Yield10 Bioscience Inc is an agricultural bioscience company. It is leveraging advanced genetics to develop the oilseed Camelina sativa as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and, in the future, PHA bioplastics for use as biodegradable bioplastics.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACON

ACOR

ADTX

ALLG

ASTS

AVTX

AWIN

CIFR

CISS

CLSK

CXAI

DCFC

GCTS

GOEV

GRTS

GUTS

JZXN

LIFW

MSTR

MVST

ORGS

PPSI

PTPI

QDEL

SIGA

SNAX

TPET

VERV

VTSI

VVPR

XTIA

YTEN

Shares of  Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.

Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

ABTS

ALAB

AMTX

ANNX

ATER

BACK

BCAN

BIOL

BNAI

BTDR

CUTR

CZOO

DNTH

EGOX

FRSX

GRDI

GRFS

GTBP

ISPR

JOAN

LAAC

LICY

LULU

LXEH

MRNO

NKTX

NVFY

OCGN

OTLK

RETO

SINT

SLNA

SMLP

TROO

Shares of  Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.

Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Earnings

Eurozone

Commodities

Global

APYX

CURI

MVLA

SPIR

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 300 points on Thursday.

The Dow traded up 0.77% to 39,814.95 while the NASDAQ rose 0.25% to 16,410.54. The S&amp;P 500 also rose, gaining, 0.38% to 5,244.72.

Crude Oil Moves Lower; Accenture Shares Tumble After Q2 Results

Yield10 Bioscience Inc

Biotech

General

NRSN

NeuroSense Therapeutics Partners With PhaseV For Clinical Trial Analysis And Optimization In Respect To ALSO Phase 3 Trial Using Advanced Causal Machine LEarning

William Blair analyst Margaret Kaczor upgrades Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) from Market Perform to Outperform.

Upgrades

Analyst Ratings

STIM

William Blair Upgrades Neuronetics to Outperform

VA Under Secretary for Health Shereef Elnahal shared insights on the &#8220;unstoppable narrative&#8221; of psychedelic medicine, fueled by compelling veterans&#8217; recovery stories and robust scientific research.
Speaking at a Horizons psychedelics conference, Elnahal noted that the Department of<a href="https://www.benzinga.com/markets/cannabis/24/02/37268305/veteran-organizations-urge-biden-and-dea-to-reform-cannabis-policy-citing-health-issues"> Veterans Affairs</a> (VA) is actively preparing for the anticipated FDA approval of psychedelics-assisted therapies, particularly for treating conditions like PTSD that prevalently affect veterans, <a href="https://www.marijuanamoment.net/top-va-official-says-psychedelics-have-surpassed-marijuana-in-bipartisan-acceptance-in-congress/">reported</a> Marijuana Moment. &#8220;We are positioning ourselves to provide these therapies the moment they&#8217;re approved, anticipating an overwhelming demand from the veteran community,&#8221; he said. 
<h2 class="wp-block-heading">VA's Role In Advancing Psychedelics Therapy</h2>
The VA, which runs programs aiming to aid veterans and members of their families, is actively funding research into clinical therapies <a href="https://www.benzinga.com/markets/cannabis/24/01/36618728/psyched-100m-for-mdma-therapy-va-funds-2024-watchlist-reform-updates-and-more">using MDMA and psilocybin</a>. &#8220;We have 13 studies happening right now; we want to take it further and strengthen the case for veterans,&#8221; Elnahal stated.
To understand why the VA is so engaged in <a href="https://www.benzinga.com/topic/mdma">MDMA </a>and <a href="https://www.benzinga.com/topic/psilocybin">psilocybin </a>treatments, particularly after years of clinical research being balked and repressed, consider this fact: 15 out of 100 veterans who served in recent wars is Iraq and Afghanistan are reportedly still suffering from PTSD in the past year and 29 will face PTSD at some time in their lives. Increasing suicide rates are also a major reason for exploring non-opioid therapies.
As more people&nbsp;start favoring psyches medical treatments, new markets start to rise. To&nbsp;learn all about the future of the cannabis industry, join us at the Benzinga Cannabis Capital Conference this October in Chicago. Hear&nbsp;directly from key industry players, advocates, experts, and policymakers. Get&nbsp;your tickets now by following&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.&nbsp;
The demand is intense and broad. Scientists and advocates argue for quicker availability of these experimental treatments, considering the ethical implications of delaying potentially effective solutions. &#8220;We are not talking about the ethics of doing this, but the ethics of not doing this,&#8221; Elnahal emphasized.
<h2 class="wp-block-heading">Broad Bipartisan Support For Medical Treatments</h2>
Elnahal highlighted the vast bipartisan support for psychedelics research, using conservative Texas Rep. Morgan Luttrell (R) as an example. Elnahal argued that this political backing is critical as it influences legislative actions to facilitate more studies and potential treatments.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="VA Under Secretary Elnahal Speaks with HB at Horizons NYC &#x7C; Studying MDMA-AT for Veterans with PTSD" width="500" height="281" src="https://www.youtube.com/embed/Pd7w6dgcwKw?start=1516&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
The House Veterans' Affairs Committee recently passed a bill requiring the VA to notify Congress if psychedelics are added to its drug formulary. President Joe Biden signed a bipartisan measure to provide funding for the Department of Defense to<a href="https://www.benzinga.com/markets/cannabis/23/12/36386091/president-biden-approves-psychedelics-clinical-trials-for-active-military-members"> conduct clinical trials</a> on the therapeutic potential of certain psychedelics for active duty military members. This was enacted under the 2024 National Defense Authorization Act (NDAA).
Read now: <a href="https://www.benzinga.com/markets/cannabis/24/05/38681854/cannabis-and-guns-this-vet-chose-the-latter-but-he-shouldnt-have-to-now-hes-going-to-federal-cou">Cannabis And Guns: This Vet Chose The Latter But He Shouldn&#8217;t Have To, Now He&#8217;s Going To Federal Court</a>

Cannabis

Psychedelics

VIDEO: Psychedelics Surpass Cannabis With Unprecedented Bipartisan Support In Congress, Says Top VA Official

WIIM

NEGG

Newegg Commerce shares are trading higher amid strength in high-short interest stocks.

IRBT

iRobot shares are trading higher amid strength in high-short interest stocks.

Scilex Holding Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>, "Scilex" or "Company")))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the 45-day review period for the U.S. Federal Trade Commission and U.S. Department of Justice to comment on or object to the Settlement Agreement (the "Settlement Agreement") entered into by the Company and its wholly owned subsidiary, Scilex Pharmaceuticals Inc. ("Scilex Pharma" and, together with the Company, the "Scilex Parties") with Takeda Pharmaceuticals U.S.A., Inc. and Takeda Pharmaceuticals Company LTD. (collectively "Takeda") to resolve the Paragraph IV patent infringement lawsuit (the "Action") that Takeda filed against the Scilex Parties in the federal district court in Delaware in November 2023 has expired and the U.S. District Court for the District of Delaware entered a Consent Judgment on May 3, 2024, approving the Settlement Agreement. The Action arose from Scilex's filing of a revised label with the FDA seeking to expand the label for its FDA-approved liquid colchicine product, Gloperba&#xAE;, a preventive treatment for gout. As part of the Settlement Agreement, the Scilex Parties entered into a License Agreement with Takeda granting the Company and its affiliates a non-exclusive license to certain patents owned by Takeda. The terms of those agreements are confidential. &nbsp;

Legal

SCLX

Scilex Holding Announce Final Court Approval Settlement Agreement With Takeda Pharmaceuticals To Resolve The Paragraph IV Patent Infringement Lawsuit

Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) reported quarterly earnings of $1.46 per share which beat the analyst consensus estimate of $1.42 by 2.82 percent. This is a 0.68 percent decrease over earnings of $1.47 per share from the same period last year. The company reported quarterly sales of $365.35 million which missed the analyst consensus estimate of $368.64 million by 0.89 percent. This is a 7.68 percent decrease over sales of $395.74 million the same period last year.

Earnings Beats

Earnings Misses

JACK

Jack In The Box Q2 Adj $1.46 Beats $1.42 Estimate, Sales $365.35M Miss $368.64M Estimate

SunPower Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) shares are trading higher Tuesday as high short-interest stocks gain amid the return of trader &#8220;Roaring Kitty&#8221; to social media. Additionally, the Biden administration raised tariffs on<a href="https://www.benzinga.com/topic/solar-panels"> Chinese solar panels</a>.
What To Know: The mania in meme stocks this week stems from a social media post from&nbsp;Keith Gill, best known as&nbsp;&#8220;Roaring Kitty&#8221;&nbsp;on YouTube and X or &#8220;DeepF&#x2A;&#x2A;&#x2A;ingValue&#8221; on Reddit.
Following a three-year hiatus from social media, Gill took to X over the weekend, posting a&nbsp;<a href="https://twitter.com/TheRoaringKitty/status/1789807772542067105" target="_blank" rel="noreferrer noopener">meme</a>&nbsp;of a person leaning forward in a chair, which sparked a rally in shares of GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) and several other heavily shorted stocks.
Gill is often credited with kicking off the meme stock craze of 2021. He posted a series of videos on YouTube leading up to the historic short squeeze in GameStop, detailing why he believed the stock was undervalued. When GameStop shares started squeezing to the upside, he began posting updates of his positions on Reddit's r/WallStreetBets.
SunPower shares are rallying as traders continue to target high short interest names. When sorting <a href="https://fintel.io/shortSqueeze">Fintel&#8217;s</a> short squeeze leaderboard by short float, SunPower<a href="https://www.benzinga.com/news/24/05/38801786/gamestop-trader-roaring-kitty-sparks-wall-street-rally-in-heavily-shorted-stocks-what-you-need-to-kn"> jumps to the top of the list</a>. According to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>, 59.04% of SunPower&#8217;s float is currently sold short. 
Separately, new CNBC <a href="https://www.cnbc.com/2024/05/14/biden-raises-china-tariffs-on-evs-solar-panels-batteries-.html#:~:text=Starting%20this%20year%2C%20President%20Joe,%25%20today%20up%20to%2025%25.">reports</a> indicate the import tax on Chinese solar cells will double this year from 25% to 50% as President Joe Biden implements tariff hikes across electric vehicles, solar panels and batteries to protect American industries from unfair competition.
&#8220;China is producing at a rate and with a trajectory that's far in excess of any plausible estimate of global demand,&#8221; a senior administration official reportedly said on a Monday.&nbsp;
&#8220;That is going to flood the global market with supply that undercuts our ability to build productive capacity at home and &#8230; leaves all of us across the world more vulnerable to economic coercion.&#8221;
See Also: <a href="https://www.benzinga.com/news/24/05/38814104/gamestop-up-triple-digits-premarket-is-2021-meme-stock-rally-back">GameStop Up Triple Digits Premarket: Is 2021 Meme Stock Rally Back?</a>
SPWR Price Action: <a href="https://www.benzinga.com/quote/SPWR">SunPower shares</a> were up 118% at $6.00 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Leopictures from Pixabay.

SPWR

SunPower Stock Is Soaring Tuesday: What's Going On?

CLNE

Clean Energy Fuels shares are trading higher after the company announced a joint development agreement with Maas Energy Works to build nine renewable natural gas production facilities at dairy farms across seven states.

Evercore ISI Group analyst Oliver Wintermantel maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a In-Line and raises the price target from $310 to $315.

Price Target

Evercore ISI Group Maintains In-Line on Williams-Sonoma, Raises Price Target to $315

Nothing Runs Like a Deere&#x2122;…including the new Skechers x John Deere footwear collection. Skechers, The Comfort Technology Company&#xAE;, and John Deere, the iconic American brand and signature leaping deer logo, are joining forces to expand the work, outdoor and fashion industries worldwide with a co-branded professional and lifestyle offering. The footwear collection hitting stores in July 2024 is designed for agricultural professionals, construction workers, outdoor enthusiasts and trendsetters—all seeking top-of-their-field brands that offer the latest innovations.

Skechers And John Deere Announce Global Footwear Partnership

Lifeway Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.24 by 33.33 percent. This is a 166.67 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $44.634 million which beat the analyst consensus estimate of $42.250 million by 5.64 percent. This is a 17.76 percent increase over sales of $37.904 million the same period last year.

LWAY

Lifeway Foods Q1 2024 GAAP EPS $0.16 Misses $0.24 Estimate, Sales $44.634M Beat $42.250M Estimate

The Dow Jones index closed lower by over 80 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Earth Science Tech</h3>
<ul>
<li>The Trade: Earth Science Tech, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ETST#OTC">ETST</a>) Director Yovan Arturo Sanchez <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 10,500 shares</a> at an average price of $0.10. To acquire these shares, it cost around $1,050.</li>
<li>What's Happening: On Jan. 29, Earth Science Tech announced a $5 million common stock repurchase program.</li>
<li>What Earth Science Tech Does: Earth Science Tech Inc is a diversified holding company. Currently, the company is focused on emerging prospects in the health and wellness industry.</li>
</ul>
<h3 class="wp-block-heading">Nanophase Technologies</h3>
<ul>
<li>The Trade: Nanophase Technologies Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NANX#OTC">NANX</a>) Director R Janet Whitmore <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,300 shares at</a> an average price of $1.40. To acquire these shares, it cost around $7,420.</li>
<li>What's Happening: On April 23, Nanophase Technologies announced financial results for the first quarter ended March 31, 2024.</li>
<li>What Nanophase Technologies Does: Nanophase Technologies Corp is engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.</li>
</ul>
<h3 class="wp-block-heading">Cerus</h3>
<ul>
<li>The Trade: Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) Director Jami K Nachtsheim <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 2,000 shares</a> at an average price of $1.79. The insider spent around $3,578 to buy those shares.</li>
<li>What's Happening: On May 2, Cerus said product revenue during the first quarter of 2024 was $38.4 million, up from $31.0 million in the year-ago period.</li>
<li>What Cerus Does: Cerus Corp is a biomedical products company focused on the field of blood transfusion safety.</li>
</ul>
<h3 class="wp-block-heading">Zomedica</h3>
<ul>
<li>The Trade: Zomedica Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#NYSE">ZOM</a>) CEO Larry C Heaton II <a href="https://www.benzinga.com/quote/RVP/analyst-ratings">acquired a total of 100,000 shares</a> at an average price of $0.14. The insider spent around $14,200 to buy those shares.</li>
<li>What's Happening: On May 9, Zomedica reported a year-over-year decease in first-quarter GAAP EPS results and issued worse-than-expected quarterly sales results.</li>
<li>What Zomedica Does: Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.</li>
</ul>
Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38807221/home-depot-paysafe-and-3-stocks-to-watch-heading-into-tuesday">Home Depot, Paysafe And 3 Stocks To Watch Heading Into Tuesday</a>

Long Ideas

Insider Trades

Pre-Market Outlook

CERS

ETST

NANX

Zomedica And 3 Other Stocks Under $3 Insiders Are Buying

Evercore ISI Group analyst Greg Melich maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Outperform and raises the price target from $66 to $67.

Evercore ISI Group Maintains Outperform on Walmart, Raises Price Target to $67

Cannabis consumption technology&nbsp;producer,&nbsp;Weedgets,&nbsp;is partnering with the American Cannabis Nurses Association (ACNA).&nbsp;Under this collaboration, Weedgets was granted rights to use the ACNA stamp on all marketing and educational&nbsp;materials as well as on updated product packaging.&nbsp;The partnership will involve co-branded advertising initiatives throughout the year.&nbsp;
&#8220;We are proud to align with the American CannabisNurses Association (ACNA),&#8221;&nbsp;stated Michael&nbsp;Barenboym,&nbsp;CEO and founder of Weedgets.&nbsp;&#8220;Our range of hardware and accessories&nbsp;was designed&nbsp;with patients in mind, and this partnership will provide greater access to those in need. We are excited to progress together!&#8221;
Benzinga asked Barenboym what&nbsp;ACNA&#8217;s&nbsp;sponsorship means&nbsp;for the company and what the nurses&#8217; association&#8217;s stamps on its products and marketing materials would mean for customers.&nbsp;
"Working with – and getting approval from – such a respected organization like the ACNA validates our commitment to consumption for all,"&nbsp;Barenboym told Benzinga.&nbsp;"Our patented integration of filtering and real-time (smoke) cooling into daily use will benefit those with weakened lungs."&nbsp;
This announcement signifies the official endorsement by ACNA of&nbsp;Weedgets&#8217;&nbsp;flagship Maze-X pipe.&nbsp;It will also involve co-creating regional showcases, educational webinars and materials, product marketing sheets and featuring thought leadership in ongoing communications and newsletters.
See Also:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/05/38685530/review-is-this-the-best-weed-pipe-on-the-market-my-experience-with-weedgets-smooth-hits-and-slee" rel="noreferrer noopener">Review &#8211; Is This The Best Weed Pipe On The Market? My Experience With Weedgets &#8211; Smooth Hits And Sleek Design</a>
&#8220;The American Cannabis Nurses Association (ACNA) is dedicated to its members, ensuring they have access to top-quality medical-grade products,&#8221;&nbsp;said ACNA president Nicole Foss in a statement.&nbsp;&#8220;Partnering with Weedgets, a renowned innovator in hardware, allows us to uphold our commitment. We look forward to launching co-branded activities throughout the year&nbsp;for the benefit of&nbsp;all our registered patients.&#8221;
<h2 class="wp-block-heading">Why Weedgets?&nbsp;</h2>
How and why did ACNA choose to partner with Weedgets?&nbsp;
"ACNA endorsed&nbsp;Weedgets'&nbsp;Maze-X pipe because of its unique focus on safer cannabis consumption through filtering and real-time cooling of the smoke,"&nbsp;Foss told Benzinga. "Weedgets&#8217;&nbsp;commitment aligns with&nbsp;ACNA&#8217;s&nbsp;mission of promoting education to patients and cannabis consumers. The&nbsp;Nurse&#8217;s&nbsp;role in cannabis medicine is to educate the consumer and discuss risk-reduction. The endorsement validates&nbsp;Weedgets&#8217;&nbsp;efforts and assures consumers of their&nbsp;product&#8217;s&nbsp;quality.&nbsp;ACNA&#8217;s&nbsp;stamp on&nbsp;Weedgets&#8217;&nbsp;packaging signifies a shared dedication to prioritizing consumer well-being and innovation."
Barenboym continued to explain the significance of the&nbsp;endorsement.&nbsp;"Using the ACNA stamp on future packaging is about more than selling more products;&nbsp;it's&nbsp;validation that we are on the right track as a company."
What's&nbsp;next?&nbsp;
"The next step in this partnership is working on our co-branded educational roll-out, including newsletters, webinars, thought leadership, and showcases, which have&nbsp;been created&nbsp;to showcase the wide range of benefits for all registered patients of the ACNA,"&nbsp;Barenboym concluded.&nbsp;
If&nbsp;you're&nbsp;interested in learning more about the vast marijuana industry, new partnerships, products and recent developments,&nbsp;don't&nbsp;miss the opportunity to join us at the&nbsp;<a target="_blank" href="https://www.benzinga.com/events/cannabis-conference/?UTM_source=article" rel="noreferrer noopener">19th Benzinga Cannabis Capital Conference</a>&nbsp;in Chicago this October 8-9. Engage with top executives, investors, policymakers, experts, and advocates to explore the&nbsp;future of the industry. Secure your tickets now before prices increase by following&nbsp;<a target="_blank" href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" rel="noreferrer noopener">this link</a>.
Courtesy photo

Maker Of Cough-Less Maze-X Pipe Gets Validation For Safer Consumption From American Cannabis Nurses Association

7 analysts have shared their evaluations of CRH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for CRH, presenting an average target of $99.71, a high estimate of $110.00, and a low estimate of $82.00. Surpassing the previous average price target of $89.34, the current average has increased by 11.61%.
<img src="https://www.benzinga.com/files/images/story/2024/1715691676_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of CRH by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Codling</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Tobias Woerner</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$82.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$106.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Michael Dudas</td>
<td>Vertical Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Justin Jordan</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$89.70</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CRH. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CRH compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of CRH's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into CRH's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CRH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CRH analyst ratings.</a>
<h2>Get to Know CRH Better</h2>
CRH is a global manufacturer of a range of building products used in construction projects, operating via a vertically integrated business model. The past decade has seen CRH transform into a leading building materials business, with increasing exposure to upstream building activities such as aggregates and cement. CRH's geographic footprint is mostly across developed markets. North America is CRH's largest market and accounts for 75% of EBITDA. The company is the largest producer of aggregates and asphalt in the US.
<h3>A Deep Dive into CRH's Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining CRH's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.65% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 1.78%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): CRH's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.57%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): CRH's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.25%, the company may face hurdles in achieving optimal financial returns.
Debt Management: CRH's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.7, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 7 Analyst Evaluations For CRH

<ul>
<li>Collaboration seeks to advance precision care by providing an alternative, non-invasive approach to the assessment of coronary physiology.</li>
<li>Both companies will focus on the integration of Medis QFR into GE HealthCare's cath lab environment built around the Allia Platform to enable a seamless user experience.</li>
</ul>
Today, GE HealthCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, and Medis Medical Imaging, a leading cardiac imaging software company, announced their collaboration aimed at helping advance precision care in the diagnosis and treatment of coronary artery disease (CAD). Together, the two companies will work to further the development and commercialization of Medis Quantitative Flow Ratio (Medis QFR), a non-invasive approach to the assessment of coronary physiology, as part of GE HealthCare's interventional cardiology portfolio built around the Allia Platform. The collaboration seeks to provide access to emerging technologies, like Medis QFR, while also reducing complexity in the cath lab to improve the operating environment for clinicians.

GEHC

GE HealthCare, Medis Medical Imaging Collaborate To Focus On Non-Invasive Coronary Assessments To Help Advance Precision Care In Treatment Of Coronary Artery Disease

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Roth MKM cut the price target for Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) from $55 to $35. Roth MKM analyst Eric Handler downgraded the stock from Buy to Neutral. Roblox shares fell 1.6% to close at $30.96 on Monday. <a href="https://www.benzinga.com/quote/RBLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham boosted the price target for Verrica Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) from $8 to $16. Needham analyst Serge Belanger maintained a Buy rating. Verrica Pharmaceuticals shares jumped 19.5% to close at $9.56 on Monday. <a href="https://www.benzinga.com/quote/VRCA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut Fortrea Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) price target from $45 to $36. Baird analyst Eric Coldwell upgraded the stock from Neutral to Outperform. Fortrea shares fell 14.9% to close at $28.11 on Monday. <a href="https://www.benzinga.com/quote/FTRE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho boosted the price target for Tencent Music Entertainment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) from $15 to $17. Mizuho analyst Wei Fang maintained a Buy rating. Tencent Music shares jumped 10.9% to close at $14.80 on Monday. <a href="https://www.benzinga.com/quote/TME/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel increased AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) price target from $81 to $86. Stifel analyst Bert Subin maintained a Buy rating. AAR shares fell 0.6% to close at $71.75 on Monday. <a href="https://www.benzinga.com/quote/AIR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Everbridge, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVBG#NASDAQ">EVBG</a>) price target from $29 to $35. Baird analyst William Power maintained a Neutral rating. Everbridge shares fell 0.1% to close at $34.71 on Monday. <a href="https://www.benzinga.com/quote/EVBG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer raised the price target for Agilysys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) from $95 to $100. Oppenheimer analyst Brian Schwartz maintained an Outperform rating. Agilysys shares fell 2% to close at $80.21 on Monday. <a href="https://www.benzinga.com/quote/AGYS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan boosted Planet Fitness, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) price target from $68 to $78. JP Morgan analyst Rahul Krotthapalli upgraded the stock from Neutral to Overweight. Planet Fitness shares rose 0.9% to close at $65.56 on Monday. <a href="https://www.benzinga.com/quote/PLNT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies increased The Boston Beer Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) price target from $335 to $360. Jefferies analyst Kaumil Gajrawala upgraded the stock from Hold to Buy. Boston Beer shares fell 2.5% to close at $283.82 on Monday. <a href="https://www.benzinga.com/quote/SAM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler raised Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) price target from $110 to $120. Piper Sandler analyst David Westenberg maintained an Overweight rating. Natera shares fell 1.9% to close at $103.33 on Monday. <a href="https://www.benzinga.com/quote/NTRA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/38814917/top-5-tech-and-telecom-stocks-which-could-rescue-your-portfolio-this-quarter">Top 5 Tech And Telecom Stocks Which Could Rescue Your Portfolio This Quarter</a>

AGYS

EVBG

FTRE

NTRA

PLNT

RBLX

VRCA

Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday

Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) has been analyzed by 28 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Ulta Beauty, presenting an average target of $556.07, a high estimate of $690.00, and a low estimate of $350.00. A 1.39% drop is evident in the current average compared to the previous average price target of $563.92. 
<img src="https://www.benzinga.com/files/images/story/2024/1715691669_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Ulta Beauty by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$476.00</td>
<td>$605.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$475.00</td>
<td>$565.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$475.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$434.00</td>
<td>$612.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$350.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Ashley Helgans</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$438.00</td>
<td>$585.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$520.00</td>
<td>$580.00</td>
</tr>
<tr>
<td>Ashley Helgans</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$585.00</td>
<td>$610.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$595.00</td>
<td>$665.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$500.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$610.00</td>
<td>$630.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$630.00</td>
<td>$575.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$525.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$540.00</td>
<td>$530.00</td>
</tr>
<tr>
<td>Stephanie Wissink</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$610.00</td>
<td>$587.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$540.00</td>
<td>$485.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$665.00</td>
<td>$635.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$565.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$630.00</td>
<td>$635.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$450.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$625.00</td>
<td>$575.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$612.00</td>
<td>$583.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$595.00</td>
<td>$595.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$600.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$635.00</td>
<td>$565.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$600.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$690.00</td>
<td>$575.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$600.00</td>
<td>$535.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ulta Beauty. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Ulta Beauty compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Ulta Beauty's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Ulta Beauty's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ULTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ulta Beauty analyst ratings.</a>
<h2>Unveiling the Story Behind Ulta Beauty</h2>
With 1,385 stores at the end of fiscal 2023 and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (41% of 2023 sales), fragrances, skin care (19% of sales), and hair care products (19% of sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
<h3>Unraveling the Financial Story of Ulta Beauty</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Ulta Beauty showcased positive performance, achieving a revenue growth rate of 10.15% as of 31 January, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ulta Beauty's net margin excels beyond industry benchmarks, reaching 11.1%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ulta Beauty's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 18.31%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Ulta Beauty's ROA stands out, surpassing industry averages. With an impressive ROA of 6.98%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Ulta Beauty's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.84.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ULTA

Deep Dive Into Ulta Beauty Stock: Analyst Perspectives (28 Ratings)

In the latest quarter, 6 analysts provided ratings for Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Manhattan Associates, revealing an average target of $238.33, a high estimate of $260.00, and a low estimate of $220.00. Surpassing the previous average price target of $232.50, the current average has increased by 2.51%.
<img src="https://www.benzinga.com/files/images/story/2024/1715691659_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Manhattan Associates. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lachlan Brown</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$260.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>George Kurosawa</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>George Kurosawa</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$260.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Manhattan Associates. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Manhattan Associates compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Manhattan Associates's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Manhattan Associates's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MANH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Manhattan Associates analyst ratings.</a>
<h2>Unveiling the Story Behind Manhattan Associates</h2>
Manhattan Associates provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers around the world.
<h3>Breaking Down Manhattan Associates's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Manhattan Associates's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 15.18%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Manhattan Associates's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 21.14%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Manhattan Associates's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 20.78%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Manhattan Associates's ROA stands out, surpassing industry averages. With an impressive ROA of 7.98%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Manhattan Associates's debt-to-equity ratio is below the industry average. With a ratio of 0.22, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MANH

A Closer Look at 6 Analyst Recommendations For Manhattan Associates

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Yield10 Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/yten-stock-quote/">YTEN</a>) just reported results for the fourth quarter of 2023.<ul><li>Yield10 Bioscience reported earnings per share of -27 cents. This was above the analyst estimate for EPS of -30 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/yten-stock-earnings-yield10-bioscience-for-q4-of-2023/">YTEN Stock Earnings: Yield10 Bioscience Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

YTEN Stock Earnings: Yield10 Bioscience Beats EPS for Q4 2023

Yield10 Bioscience, Inc. 2023 Q4 - Results - Earnings Call Presentation

Yield10 Bioscience, Inc. (YTEN) Q4 2023 Earnings Call Transcript

Lake Street analyst Ben Klieve reiterated a Hold rating on Yield10 Bioscience (YTEN – Research Report) today and set a price target of $0.50. Ben K...

Balancing Potential Growth with Financial Challenges: A Hold Rating for Yield10 Bioscience

Maxim Group analyst Anthony Vendetti has maintained their neutral stance on YTEN stock, giving a Hold rating yesterday. Anthony Vendetti has given ...

Hold Recommendation on Yield10 Bioscience Amid Commercialization and Capital Uncertainties

Yield10 Bioscience files to sell 6.38M shares of common stock for holders

Yield10 Bioscience to implement reverse stock split

Yield10 Bioscience files to sell units

ORGN, LGO and CMT are among materials movers

PLL, TSE and FF are among materials movers

CRML

HGAS

LOMA

NTIC

ORGN

SEED

SLSR

USAU

Press Releases

USDA-APHIS Determines that Yield10 Bioscience's Stacked Herbicide Tolerant Camelina May Be Planted and Bred in the United States

Yield10 Bioscience Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil

Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program

Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock

Health Care

Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests

USDA-APHIS Determines that Yield10 Bioscience's Omega-3 Camelina Varieties May Be Planted and Bred in the United States

Yield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for Planting in Canada

Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024

Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Yield10 Bioscience Stock (NASDAQ:YTEN), Short Interest Report

People Also Watch